Back to Trades
Total Value
$0
Filing Date
Jul 24, 2026
1 transactions
Trade Summary
On Jul 22, 2026, Redmile Group, LLC, Director, reported $0 of Atara Biotherapeutics, Inc. (ATRA) across 1 transactions. The filing covers Common Stock and reflects balanced net activity of $0. Insider transactions are sourced from SEC Form 4 disclosures and should be reviewed alongside company fundamentals and the insider's broader trading history.
Company Information
- Company Name
- Atara Biotherapeutics, Inc.
- Ticker Symbol
- ATRA
- CIK
- 0001604464
Insider Information
- Role
- Director
- Location
- LARKSPUR, CA
Filing Details
- Filing Date
- Jul 24, 2026
- Transaction Date
- Jul 22, 2026
- Accession Number
- 0001104659-26-086733
- Form Type
- 4
Non-Derivative Transactions
| Date | Security | Shares | Price | Type | Value |
|---|---|---|---|---|---|
| Jul 22, 2026 | Common Stock | 195,211 | — | Exercise | — |
| Jul 22, 2026 | Common Stock | 60 | — | Tax Withholding | — |
Derivative Transactions
| Date | Security | Shares | Exercise Price | Type | Value |
|---|---|---|---|---|---|
| Jul 22, 2026 | ATRA derivative | 101,089 | — | Exercise | — |
| Jul 22, 2026 | ATRA derivative | 38,735 | — | Exercise | — |
| Jul 22, 2026 | ATRA derivative | 55,387 | — | Exercise | — |
Want live alerts when Redmile Group, LLC trades again?
Download Insider Trades to track ATRA, follow insiders, and get mobile alerts when new SEC Form 4 filings are published.
Footnotes
- (F1)The Pre-Funded Warrants are exercisable at any time on or after the original issuance on July 23, 2019 until the seven-year anniversary of the original issuance date, at an exercise price equal to $0.0025 per share, subject to a 9.99% beneficial ownership blocker.
- (F2)The Pre-Funded Warrants are exercisable at any time on or after the original issuance on May 29, 2020 until the seven-year anniversary of the original issuance date, at an exercise price equal to $0.0025 per share, subject to a 9.99% beneficial ownership blocker.
- (F3)The Pre-Funded Warrants are exercisable at any time on or after the original issuance on December 11, 2020 until the seven-year anniversary of the original issuance date, at an exercise price equal to $0.0025 per share, subject to a 9.99% beneficial ownership blocker.
- (F4)The reported securities are directly owned by certain private funds managed by Redmile Group, LLC (collectively, the "Funds") and may be deemed beneficially owned by Redmile Group, LLC ("Redmile") as investment manager of the Funds. The reported securities may also be deemed beneficially owned by Jeremy Green as the principal of Redmile. Each of Redmile and Mr. Green (the "Reporting Persons") disclaims beneficial ownership of the reported securities except to the extent of their pecuniary interest therein, if any. This report shall not be deemed an admission that such Reporting Persons are the beneficial owners of the securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended, or for any other purpose.
- (F5)On July 22, 2026, the Reporting Persons exercised the reported Pre-Funded Warrants through a "cashless exercise" resulting in the Issuer withholding 60 shares of Common Stock to pay the exercise price and issuing the remaining 195,151 shares of Common Stock to the applicable Funds. The number of shares withheld to pay the aggregate exercise price for the cashless exercise of the Pre-Funded Warrants was based on the closing sale price per share of the Common Stock on the trading date immediately prior to the exercise date, per the terms of the Pre-Funded Warrants.
- (F6)The Pre-Funded Warrants are exercisable at any time on or after the original issuance date, at an exercise price equal to $0.0025 per share, subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants have no expiration date.
- (F7)The Pre-Funded Warrants are exercisable at any time on or after the original issuance date, at an exercise price equal to $0.0001 per share, subject to a 9.99% beneficial ownership blocker. The Pre-Funded Warrants have no expiration date.
- (F8)The previous report on Form 3 inadvertently indicated that all of the Pre-Funded Warrants beneficially owned by the Reporting Persons have an exercise price of $0.0001 per share and no expiration date. Footnotes (1), (2), (3), (6) and (7) and the related disclosures correct the Form 3 with respect to the terms of the Pre-Funded Warrants beneficially owned by the Reporting Persons.